利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.04 秒)

    14-3-3 ZETA OVER-EXPRESSION AS A POOR PROGNOSIS FACTOR, AND A THERAPEUTIC TARGET IN MULTIPLE CANCER TYPE
    1.
    发明申请
    14-3-3 ZETA OVER-EXPRESSION AS A POOR PROGNOSIS FACTOR, AND A THERAPEUTIC TARGET IN MULTIPLE CANCER TYPE 失效
    14-3-3 ZETA超表达作为不良预后因素，多种癌症类型的治疗目标

    公开(公告)号：US20080318231A1

    公开(公告)日：2008-12-25

    申请号：US11950264

    申请日：2007-12-04

    申请人： DIHUA YU ,  Jun Yao ,  Christopher L. Neal ,  Wentao Yang ,  Xiaoyan Zhou ,  Raphael E. Pollock ,  Mien-Chie Hung ,  Jun Yang ,  Ping Li ,  Nina T. Nguyen

    发明人： DIHUA YU ,  Jun Yao ,  Christopher L. Neal ,  Wentao Yang ,  Xiaoyan Zhou ,  Raphael E. Pollock ,  Mien-Chie Hung ,  Jun Yang ,  Ping Li ,  Nina T. Nguyen

    IPC分类号： C12Q1/68

    CPC分类号： G01N33/574 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/178

    摘要： Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.

    摘要翻译： 公开了确定患有过度增生性疾病的受试者的预后的方法，包括确定受试者中14-3-3ζ的表达和/或功能。 还公开了制备调节凋亡的药剂的方法，包括获得一种或多种候选物的步骤，测试一种或多种候选物质以确定其调节14-3-3ζ的表达和/或功能的能力， 选择确定调节14-3-3ζ的表达和/或功能的候选物质，并制备包含所选候选物质的药物组合物。 此外，公开了通过本发明所述的方法制备药剂并且将药剂施用于受试者的治疗患有过度​​增殖性疾病的受试者的方法。 过度增生性疾病可以是癌症，例如乳腺癌。

    14-3-3 Zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer type
    2.
    发明授权
    14-3-3 Zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer type 失效
    14-3-3 Zeta过表达作为不良预后因素，是多种癌症类型的治疗靶点

    公开(公告)号：US07709205B2

    公开(公告)日：2010-05-04

    申请号：US11950264

    申请日：2007-12-04

    申请人： Dihua Yu ,  Jun Yao ,  Christopher L. Neal ,  Wentao Yang ,  Xiaoyan Zhou ,  Raphael E. Pollock ,  Mien-Chie Hung ,  Jun Yang ,  Ping Li ,  Nina T. Nguyen

    发明人： Dihua Yu ,  Jun Yao ,  Christopher L. Neal ,  Wentao Yang ,  Xiaoyan Zhou ,  Raphael E. Pollock ,  Mien-Chie Hung ,  Jun Yang ,  Ping Li ,  Nina T. Nguyen

    IPC分类号： C12Q1/68

    CPC分类号： G01N33/574 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/178

    摘要： Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.

    摘要翻译： 公开了确定患有过度增生性疾病的受试者的预后的方法，包括确定受试者中14-3-3ζ的表达和/或功能。 还公开了制备调节凋亡的药剂的方法，包括获得一种或多种候选物的步骤，测试一种或多种候选物质以确定其调节14-3-3ζ的表达和/或功能的能力， 选择确定调节14-3-3ζ的表达和/或功能的候选物质，并制备包含所选候选物质的药物组合物。 此外，公开了通过本发明所述的方法制备药剂并且将药剂施用于受试者的治疗患有过度​​增殖性疾病的受试者的方法。 过度增生性疾病可以是癌症，例如乳腺癌。

    14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types
    3.
    发明授权
    14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types 有权
    14-3-3ζ过表达作为一种不良预后因子，是多种癌症类型的治疗靶点

    公开(公告)号：US07316907B2

    公开(公告)日：2008-01-08

    申请号：US10938387

    申请日：2004-09-10

    申请人： Dihua Yu ,  Jun Yao ,  Christopher L. Neal ,  Wentao Yang ,  Xiaoyan Zhou ,  Raphael E. Pollock ,  Mien-Chie Hung ,  Jun Yang ,  Ping Li ,  Nina T. Nguyen

    发明人： Dihua Yu ,  Jun Yao ,  Christopher L. Neal ,  Wentao Yang ,  Xiaoyan Zhou ,  Raphael E. Pollock ,  Mien-Chie Hung ,  Jun Yang ,  Ping Li ,  Nina T. Nguyen

    IPC分类号： G01N33/53 ,  G01N33/574

    CPC分类号： G01N33/574 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/178

    摘要： Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.

    摘要翻译： 公开了确定患有过度增生性疾病的受试者的预后的方法，包括确定受试者中14-3-3ζ的表达和/或功能。 还公开了制备调节凋亡的药剂的方法，包括获得一种或多种候选物的步骤，测试一种或多种候选物质以确定其调节14-3-3ζ的表达和/或功能的能力， 选择确定调节14-3-3ζ的表达和/或功能的候选物质，并制备包含所选候选物质的药物组合物。 此外，公开了通过本发明所述的方法制备药剂并且将药剂施用于受试者的治疗患有过度​​增殖性疾病的受试者的方法。 过度增生性疾病可以是癌症，例如乳腺癌。